drugset / Trial / NCT07111832
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with Toripalimab combined with Nab-paclitaxel, as assessed by blinded independent central review (BICR).
Timeline
- Start
- 2025-08-20
- Primary completion
- 2028-03
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Toripalimab | Monoclonal antibody | — | — |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | — |